Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia Leukemia (2004) Imatinib mesylate is a signal transduction inhibitor that specifically targets a set of protein tyrosine kinases, abl, c-kit, platelet-derived growth factor receptor (PDGF-R). [1] [2] [3] In chronic myeloid leukemia (CML), this drug shows impressive efficacy, with rates of complete hematological response of 95%. 1 Common nonhematological side effects reported in the literature have included nausea, fluid retention with weight gain, muscle cramps and fatigue. 4 A recent publication of Milojkovic et al 5 has reported the dermatological toxicity secondary to Imatinib therapy, with the description of a unique dermatitis related to this drug and a possibility of severe adverse cutaneous reactions. Herein, we describe another possible dermatological side effect that can be precipitated by Imatinib: porphyria cutanea tarda (PCT). A 67-year-old woman was diagnosed at our Institute in 1988 as having CML and was treated with interferon (IFN)-alpha from 1988 to 1993. She achieved complete hematological response, in the absence of cytogenetic remission. In 1993, while undergoing IFN treatment, the patient reported the appearance of spontaneous and painless hemorrhagic blisters on the sunexposed surface of both hands and both feet. Skin biopsy demonstrated lymphohistiocytic infiltrate of the derma. Porphyrin fractions were tested and a high level of uroporphyrin was found in random urine samples (64.8%, normal o20%), leading to the diagnosis of PCT. IFN treatment was discontinued and the patient was treated only with hydroxyurea, with complete resolution of the skin lesions and the return of porphyrin levels to normal. In November 2000, the CML progressed to a blastic crisis, and Imatinib at 600 mg/daily was administered; successful control of leukocytosis was only obtained on increasing the dose to 800 mg/daily, at 14 weeks of therapy. After 108 weeks of continuous Imatinib therapy, the patient noted the appearance of the same painful blisters on her hands, feet and legs. The uroporphyrin level was 64.9% (normal o20%), with total urinary levels of 27.364 mg/24 h (normal 0.50) and liver parameters were normal. Imatinib treatment was discontinued; the skin lesions showed almost complete resolution and laboratory parameters improved.
In PCT, photoactivation of the complement system in the presence of uroporphyrin results in the activation of dermal mast cells, which release their proteases. This results in dermalepidermal separation, reflected clinically as skin fragility and vesicles. The interaction between activated mast cells with fibroblasts, the nature of which is still unclear, may contribute to fibrosis and sclerodermoid skin changes. The stimulatory effect of uroporphyrin on collagen biosynthesis by fibroblasts, which occurs independent of irradiation, may be responsible for the sclerodermoid lesions seen at sun-exposed as well as sunprotected areas. 6 Imatinib should be considered as one of the factors capable of triggering or exacerbating this unusual skin complication, as perhaps should IFN. In fact, in our case, PCT was also precipitated by IFN therapy, an event which has also been reported by others. 7 Regarding the mechanisms underlying this event, interference with enzymatic pathways of uroporphyrin decarboxylation or through inhibition of PDGF-R of dermal cells may be involved, although these mechanisms need to be better defined.
We highlight the importance of considering a diagnosis of PCT in resistant CML patients treated with Imatinib at high dosage, who developed painful skin blisters during treatment. 
